Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Airlines Group Inc (AAL) vs Novavax Inc (NVAX) Price & Performance

American Airlines Group IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

American Airlines Group Inc vs Novavax Inc — how do they compare? American Airlines Group Inc trades at $15.04 (market cap $10.55B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: American Airlines Group Inc is far larger — about 8.1× Novavax Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

AALNVAX
Market Cap
$10.55B$1.31B
Sector
IndustrialsHealth
52-Week High
$18.15$11.19
52-Week Low
$10.18$6.22
Enterprise Value
$38.51B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Airlines Group Inc

American Airlines (AAL) trades at $14.94, down 0.43% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth but negative net income margin (-0.56%) and elevated P/E of 43.73. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.03 expected, while Q4 2025 missed estimates. Cash flow remains positive with $154M net cash flow in 2025. Analyst consensus is mixed with 44.7% buy ratings and $19.63 price target, representing 31% upside.

AAL presents a turnaround opportunity with premium revenue growth and debt reduction, but faces significant headwinds from fuel costs and negative equity. The stock trades below analyst targets but requires sustained profitability improvement to justify current valuation multiples. Key risks include fuel price volatility and competitive pressure in the airline industry.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Airlines Group Inc

American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

Read more on AAL

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX